Biocon

FACTSHEET

ENHANCING GLOBAL HEALTHCARE

Biocon Limited, publicly listed in 2004, is an innovation-led global biopharmaceuticals company committed to enhancing affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune diseases.

Biocon has pursued business leadership on a platform of affordable access to essential and life-saving medicines, which encompass novel biologics, generic and biosimilar drugs. Biocon is one of the biggest global suppliers of complex small molecule APIs and a leading biosimilars player, with a wide portfolio of insulins, monoclonal antibodies and conjugated recombinant protein.

Biocon Biologics Limited, a subsidiary of Biocon Limited, is a fully integrated global biosimilars organization. It is leveraging cutting-edge science, innovative tech platforms and advanced research & development capabilities to lower treatment costs of biologics therapies while improving healthcare outcomes. It has a strong research pipeline of biosimilar molecules across diabetes, oncology, immunology, and other non- communicable diseases. Five molecules from Biocon Biologics' portfolio have been taken from lab to market, in developed markets like United States, EU, Australia, Canada and Japan. It has many firsts to its credit including the most recent USFDA approval of world's first interchangeable biosimilar, awarded to its Insulin Glargine, which has been launched in the US in 2021. Biocon Biologics is pursuing its path towards transforming healthcare and transforming lives by enabling affordable access to millions of patients' worldwide.

Syngene International Limited, Biocon's publicly listed discovery, development and manufacturing services subsidiary, provides integrated scientific services to life sciences companies around the world. Through its wide portfolio of healthcare products and services, Biocon is ensuring better patient care and improved treatment outcomes while reducing costs for wider access to affordable, quality assured, complex therapies.

While pursuing its purpose of using biotechnology to develop therapies that heal the world, Biocon remains dedicated to advancing the health of our patients, our planet and our business.

A CREDIBLE BIOPHARMA ENTERPRISE

120+
Countries

1,280+
Patents granted

1,028#
Registered trademarks

Top 10
Biosimilar players by global revenue in 2021

50+
cGMP approvals from International regulatory agencies*

Top 15
Among Top 15 Companies from India on Dow Jones Sustainability Emerging Markets Index

Key Brands in India INSUGEN® (rh-insulin), Basalog One® (prefilled Glargine pen), CANMAb® (Trastuzumab), BIOMAb-EGFR® (Nimotuzumab) and ALZUMAb-L® (Itolizumab)

Biologics+Generics

GROWTH VERTICALS

From pipeline to production, from drug discovery to drug delivery, we bring differentiated, high-quality and affordable healthcare products & services globally.

Biocon
GENERICS

Ensuring access through quality, affordability, reliability

Biocon Biologics
BIOSIMILARS

Expanding access through innovative, inclusive healthcare solutions

Syngene
RESEARCH SERVICES

Partnering to deliver innovative scientific solutions

BICARA therapeutics
NOVEL BIOLOGICS

Pushing scientific boundaries to deliver impactful innovations

BIOCON : FINANCIAL SNAPSHOT

₹73,603
Million*
(Annual revenue)

₹7,405
Million*
(Annual profit)

₹6,270
Million*
(Gross R&D spend)

27%
EBITDA margin*

13,500+
Total employees*

₹6.2
EPS*

*All the numbers are FY21

REVENUE BREAK-UP

BUSINESS REVENUE CONTRIBUTION# FY 21

- **31%** Generics
- **37%** Biologics
- **29%** Research Services
- **3%** Other Income

#Includes inter-segment revenue

GEOGRAPHIC DISTRIBUTION FY 21

- **19%** Domestic
- **81%** International

TALENT PROFILE

FY 21*

- **43%** Post Graduates & PhDs
- **15%** Others
- **41%** Graduates

*Biocon + Biocon Biologics, India + Biocon Biologics, Malaysia

GLOBAL SCALE MANUFACTURING CAPABILITIES

- Competitive edge in APIs through expertise in fermentation technology, large scale chromatography & synthetic chemistry
- State-of-the-art manufacturing facilities – mammalian & microbial . Facilities conform to most stringent cGMP guidelines
- Global Scale Biologics Manufacturing Capability; both Drug Substance & Drug Product
- Regulatory approvals-EMA, US FDA, Health Canada, ANVISA, COFEPRIS, PMDA, TGA, MCC etc

MANUFACTURING LOCATIONS :

Bengaluru | Telangana | Visakhapatnam | Malaysia

Biocon Limited, 20th KM, Hosur Road, Electronic City, Bengaluru, India 560 100
Phone: +91 80 2808 2808/91 80 4014 4014 | Fax: +91 80 2852 3423
Email: Group.Communications@biocon.com | Website: www.biocon.com
Twitter: @Bioconlimited | LinkedIn: /company/biocon/ | Facebook: @Bioconlimited

Follow us at